Novo Nordisk is rebuilding parts of its workforce after a year of significant layoffs, adding around 2,000 employees in 2026 as it sharpens focus on high-growth areas. The hiring marks a clear transition from broad cost-cutting to more selective talent investment.
The company had reduced its headcount by nearly 7,800 roles in 2025, its largest workforce reduction to date. The move was part of a restructuring effort led by Mike Doustdar, CEO, aimed at improving efficiency and redirecting resources toward key business segments. These include its fast-growing portfolio of diabetes and obesity treatments.
The latest hiring push reflects a more calibrated approach. Instead of expanding across all functions, the company is focusing on roles aligned with long-term priorities. Recruitment is expected to support areas such as production, research and commercial operations tied to its core therapies.
This dual strategy highlights an ongoing reset within the organisation. By reducing roles in some areas while strengthening others, Novo Nordisk is reshaping its structure to match evolving business demands. The approach also suggests tighter control over costs, even as the company invests in growth.
The scale of both layoffs and hiring underlines the depth of change underway. After years of steady workforce expansion, the company has adopted a more flexible model that allows for sharper shifts in resource allocation.
The move reflects a broader trend across the pharmaceutical sector. Companies are increasingly reallocating talent toward high-value therapies and innovation-led functions, while trimming roles in slower-growth areas. For Novo Nordisk, this balancing act is central to staying competitive in a market shaped by rising demand, pricing pressures and rapid scientific advancement.
